{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:10:43Z","timestamp":1794471043783,"version":"4.9.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Immune checkpoint\u2013inhibitor (ICI) colitis is a common adverse event that is primarily treated with corticosteroids but may require selective immunosuppressive therapy (SIT). Although endoscopic features have been associated with SIT use, it remains unclear whether these associations differ by ICI type.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a 2-center retrospective cohort study and included patients with histologically confirmed ICI colitis. Endoscopic images were reviewed by gastroenterologists specialized in inflammatory bowel disease (IBD) and scored using the Mayo score and the Immune-Mediated Colitis Endoscopic Score (IMCES). Early SIT use was defined as SIT use within 3\u2009weeks after the start of colitis treatment. Features associated with SIT use were stratified by ICI type, and discriminative performance was evaluated using receiver operating characteristic (ROC) analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 255 included patients, 38% required SIT. Biochemical parameters associated with early SIT use were C-reactive protein (CRP) (odds ratio (OR), 1.41; P\u2009=\u2009.005), and albumin (OR, 0.92; P\u2009=\u2009.020). Endoscopic features associated with SIT use included erythema (OR, 4.09; P\u2009=\u2009.006) and exudate (OR, 3.24; P\u2009=\u2009.012), which were limited to patients treated with anti-cytotoxic T-lymphocyte-associated antigen 4\u2013based (aCTLA-4\u2013based) therapy. In multivariable analysis, ICI type remained the only variable associated with early SIT use (OR, 12.8; P\u2009&amp;lt;\u2009.001). The IMCES demonstrated areas under the curves (AUCs) of 0.57 (95% CI, 0.50-0.65) for overall and 0.61 (95% CI, 0.53-0.69) for early SIT use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with ICI colitis, escalation to SIT use was primarily associated with ICI type, with limited additional value of biochemical or endoscopic features. The IMCES showed poor predictive performance in this external validation cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izag104","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:20:24Z","timestamp":1779794424000},"page":"2118-2128","source":"Crossref","is-referenced-by-count":4,"title":["Clinical and endoscopic features of checkpoint inhibitor\u2013induced colitis and their association with selective immunosuppressive therapy use"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6546-3765","authenticated-orcid":false,"given":"Myrthe R","family":"Naber","sequence":"first","affiliation":[{"name":"University Medical Centre Utrecht, Utrecht University Department of Gastroenterology and Hepatology, , Heidelberglaan 100 , Utrecht, 3584 CX,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mick J M","family":"van Eijs","sequence":"additional","affiliation":[{"name":"University Medical Centre Utrecht, Utrecht University Department of Oncology, , Heidelberglaan 100 , Utrecht, 3584 CX,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jildou S","family":"Huitema","sequence":"additional","affiliation":[{"name":"University Medical Centre Groningen Department of Gastroenterology and Hepatology, , Hanzeplein 1 , Groningen, 9713 GZ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacco J","family":"de Haan","sequence":"additional","affiliation":[{"name":"University Medical Centre Groningen Department of Oncology, , Hanzeplein 1 , Groningen, 9713 GZ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karijn P M","family":"Suijkerbuijk","sequence":"additional","affiliation":[{"name":"University Medical Centre Utrecht, Utrecht University Department of Oncology, , Heidelberglaan 100 , Utrecht, 3584 CX,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijn C","family":"Visschedijk","sequence":"additional","affiliation":[{"name":"University Medical Centre Groningen Department of Gastroenterology and Hepatology, , Hanzeplein 1 , Groningen, 9713 GZ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona D M","family":"van Schaik","sequence":"additional","affiliation":[{"name":"University Medical Centre Utrecht, Utrecht University Department of Gastroenterology and Hepatology, , Heidelberglaan 100 , Utrecht, 3584 CX,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"2026103014075877900_izag104-B1","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/S41467-020-17670-Y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"2026103014075877900_izag104-B2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/SCIENCE.AAR4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"2026103014075877900_izag104-B3","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/J.CGH.2020.01.033\/ASSET\/E2578ADE-6D56-4EB3-9D0F-35E33723232E\/MAIN.ASSETS\/FX1.JPG","article-title":"Management of patients with immune checkpoint inhibitor-induced enterocolitis: a systematic review","volume":"18","author":"Collins","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026103014075877900_izag104-B4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4143\/CRT.2020.790","article-title":"The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients","volume":"53","author":"Tang","year":"2021","journal-title":"Cancer Res Treat"},{"key":"2026103014075877900_izag104-B5","author":"Cancer Institute N","year":"2026"},{"key":"2026103014075877900_izag104-B6","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/J.ANNONC.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"2026103014075877900_izag104-B7","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"key":"2026103014075877900_izag104-B8","doi-asserted-by":"publisher","first-page":"114172","DOI":"10.1016\/j.ejca.2024.114172","article-title":"Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma","volume":"207","author":"Verheijden","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026103014075877900_izag104-B9","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1200\/JCO.24.00191\/SUPPL_FILE\/DS_JCO.24.00191.PDF","article-title":"Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials","volume":"42","author":"Verheijden","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026103014075877900_izag104-B10","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-19-3322\/75878\/AM\/ASSOCIATION-OF-ANTI-TNF-WITH-DECREASED-SURVIVAL-IN","article-title":"Association of Anti-TNF with decreased survival in steroid refractory ipilimumab and Anti-PD1-treated patients in the dutch melanoma treatment registry","volume":"26","author":"Verheijden","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026103014075877900_izag104-B11","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1001\/JAMAONCOL.2022.5041","article-title":"Association of immune-related adverse event management with survival in patients with advanced melanoma","volume":"8","author":"Van Not","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026103014075877900_izag104-B12","doi-asserted-by":"publisher","first-page":"e000451","DOI":"10.1136\/JITC-2019-000451","article-title":"Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis","volume":"8","author":"Mooradian","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026103014075877900_izag104-B13","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1177\/10781552241248057\/ASSET\/IMAGES\/LARGE\/10.1177_10781552241248057-FIG8.JPEG","article-title":"Evaluation of colitis induced by immune-checkpoint inhibitors therapy in melanoma patients by an overall grading scale","volume":"31","author":"Nguyen","year":"2025","journal-title":"J Oncol Pharm Pract"},{"key":"2026103014075877900_izag104-B14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/S41416-020-0882-Y","article-title":"Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?","volume":"123","author":"Cheung","year":"2020","journal-title":"Br J Cancer"},{"key":"2026103014075877900_izag104-B15","doi-asserted-by":"publisher","first-page":"e000278","DOI":"10.1136\/ESMOOPEN-2017-000278","article-title":"Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management","volume":"3","author":"Geukes Foppen","year":"2018","journal-title":"ESMO Open"},{"key":"2026103014075877900_izag104-B16","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/IBD\/IZY104","article-title":"Endoscopic and histologic features of immune checkpoint inhibitor-related colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2026103014075877900_izag104-B17","doi-asserted-by":"publisher","first-page":"102536","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade\u2014a worldwide perspective","volume":"70","author":"Gougis","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026103014075877900_izag104-B18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/S11523-025-01135-7","article-title":"Differential disease behavior of immune-mediated colitis among different types of immune checkpoint inhibition","volume":"20","author":"Shatila","year":"2025","journal-title":"Target Oncol"},{"key":"2026103014075877900_izag104-B19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/J.GIE.2024.01.024","article-title":"Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patients","volume":"100","author":"Wang","year":"2024","journal-title":"Gastrointest Endosc"},{"key":"2026103014075877900_izag104-B20","doi-asserted-by":"publisher","DOI":"10.1016\/J.IGIE.2025.09.002","article-title":"Validation of the immune-mediated colitis endoscopic score using a retrospective cohort of patients with immune-mediated colitis","author":"Shatila","year":"2025","journal-title":"iGIE"},{"key":"2026103014075877900_izag104-B21","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1053\/J.GASTRO.2006.12.038\/ATTACHMENT\/86A4AA4B-246E-40C2-99EA-7FDDE8106F86\/MMC1.PDF","article-title":"A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis","volume":"132","author":"D\u2019Haens","year":"2007","journal-title":"Gastroenterology"},{"key":"2026103014075877900_izag104-B22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.gie.2024.10.007","article-title":"Endoscopic scoring of immune-mediated colitis disease activity","volume":"101","author":"Bergqvist","year":"2025","journal-title":"Gastrointest Endosc"},{"key":"2026103014075877900_izag104-B23","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1053\/J.GASTRO.2022.12.007","article-title":"AGA clinical practice guideline on the role of biomarkers for the management of ulcerative colitis","volume":"164","author":"Singh","year":"2023","journal-title":"Gastroenterology"},{"key":"2026103014075877900_izag104-B24","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1053\/J.GASTRO.2023.09.029","article-title":"AGA clinical practice guideline on the role of biomarkers for the management of Crohn\u2019s disease","volume":"165","author":"Ananthakrishnan","year":"2023","journal-title":"Gastroenterology"},{"key":"2026103014075877900_izag104-B25","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/J.CGH.2014.07.055","article-title":"A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis","volume":"13","author":"Arias","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026103014075877900_izag104-B26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/JGH3.12506","article-title":"Low serum albumin at admission is a predictor of early colectomy in patients with moderate to severe ulcerative colitis","volume":"5","author":"Tanaka","year":"2021","journal-title":"JGH Open"},{"key":"2026103014075877900_izag104-B27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/S40425-018-0411-1","article-title":"Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J Immunother Cancer"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/11\/2118\/70754802\/izag104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/11\/2118\/70754802\/izag104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:08:06Z","timestamp":1793383686000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/11\/2118\/8767723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,8,21]]},"published-print":{"date-parts":[[2026,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izag104","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,8,21]]}}}